Leite NC, et al. - In patients with type 2 diabetes and non-alcoholic fatty liver disease (NAFLD), researchers evaluated the effectiveness of diacerein in improving liver fibrosis and steatosis. They randomized diabetic patients with NAFLD to 24-month treatment with placebo (n=35) or diacerein 100 mg/day (n=34). The difference in mean liver stiffness and steatosis (evaluated by transient elastography [Fibroscan^®] at baseline, and 12 and 24 months of follow-up) changes during treatment was the primary outcome. According to findings, 2-year diacerein treatment in diabetic patients with NAFLD significantly reduced liver fibrosis.